MINDBIO
THERAPEUTICS
BREAKTHROUGH
DISCOVERY IN MICRODOSING CLINICAL TRIAL REVEALS SIGNIFICANT
POSITIVE EFFECTS ON QUALITY OF SLEEP
-
New
Discovery:
MindBio's
LSD-Microdosing Treatment Improves Sleep
-
Significant
Intellectual Property Advancement & Know How
-
Completed:
Extensive Analysis of LSD-Microdosing Data from 3231 Nights of
Sleep
-
Statistically
Significant Results:
MindBio is
pleased to report statistically significant improvements in quality
of sleep discovered in the LSD-Microdosing group vs Placebo
group
Vancouver,
British Columbia – June 14, 2023 -- InvestorsHub NewsWire --
MindBio
Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the "Company"
or "MindBio"),
is pleased to report its major
discovery from sleep data obtained from randomized controlled
trials LSD-Microdosing from 3231 nights of sleep in 80 clinical
trial participants.
MindBio's LSD-Microdosing clinical trials
have yielded positive top line data including statistically
significant enhancements in subjective feelings of "wellness",
"creativity", "happiness", "social connectivity" and
"energy". The sleep data collected from the trial
adds to MindBio's intellectual property in a Big Data play for the
Company. MindBio scientists are preparing a further 7 subsequent
upcoming papers analysing data from Phase 1 LSD-Microdosing
randomized controlled trials in 80 healthy subjects ahead of two
Phase 2 LSD-Microdosing trials starting shortly.
MindBio is pleased to report preliminary
findings from sleep data obtained from 3231 nights of sleep,
recording, measuring and analysing the sleep patterns of
participants in the LSD-Microdosing treatment group n=40 against
the placebo group n=40. The Company is pleased to announce it has
made a major discovery
confirmatory of positive sleep responses to MindBio's LSD-Microdosing
treatment.
Not only does LSD-Microdosing
improve subjective feelings of mood and feelings of happiness,
energy, creativity, social connectivity and wellness, it also has a
statistically significant impact on
quality of sleep.
Why is positive sleep
data from LSD-Microdosing so important?
The ground-breaking findings are important,
particularly in depression, and some related mental health
conditions where MindBio has a scientific interest, such as
pre-menstral dysmorphic disorder, where quality of sleep is
disproportionately compromised and seen as a significant
contributor to down-spiralling mental health. A common first line of treatment to mood
and sleep disruption is the use of anti-depressants plus sleeping
pills.
Sleeping pills pose a potential
reliance, misuse and addiction risk and the negative unacceptable
side effects from anti-depressants (such as weight gain, agitation,
gastro-intestinal upset and sexual impotence) are well
reported.1
The positive sleep data from
MindBio's proprietary LSD-Microdosing treatment is ground-breaking
in respect of potentially replacing existing treatments for mood
and sleep disruption that are often ineffective and have
unacceptable side effects. MindBio's discovery adds to the Company's
Big Data strategy, adding to its intellectual property to
effectively treat patients with mental health disorders through
MindBio's proprietary LSD-Microdosing treatment program.
Phase 2 LSD-Microdosing
trials to begin shortly.
MindBio has two fully funded Phase 2
LSD-Microdosing clinical trials starting shortly. The first trial
focuses on Major Depressive Disorder, where 20 patients meeting
DSM-V criteria will receive an open label 8-week LSD microdosing
treatment regimen in a naturalistic at-home setting. This trial
will serve as the basis for continuing a much larger Phase 2b
triple-dummy, active placebo-controlled trial in depressed
patients. The second trial explores the effectiveness of
LSD-Microdosing in conjunction with Meaning Centred Psychotherapy
in late-stage cancer patients experiencing emotional distress. This
randomized, double-blind, and placebo-controlled trial will involve
40 participants and is set to begin recruiting participants for the
trial shortly.
Chief Executive Officer and Co-Founder of
MindBio Therapeutics said "We are delighted by the continued
progress we see in the effectiveness and tolerability of MindBio's
proprietary LSD-Microdosing program. The sleep data is promising for a potential
tolerable alternative to sleeping pills and we are rigorously
pursuing masses of data on LSD-Microdosing under randomized
controlled conditions to get the evidence we need for accelerating
approvals for access to this medicine for effectively treating mood
and sleep disruption".
MindBio's investment thesis, using
microdosing, centers on the creation of a unique treatment model
that is globally scalable, safe, accessible, and affordable, aiming
to address the existing challenges in mental health
care.
We invite you to join us in support of
creating a brighter future for mental health.
Receive our latest updates
here:
https://www.mindbiotherapeutics.com/get-updates
Follow MindBio
on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true
Follow CEO
Justin Hanka on LinkedIn:
https://www.linkedin.com/in/justinhanka/
For
further information, please contact:
Justin
Hanka, Chief Executive Officer
61
433140886
justin@mindbiotherapeutics.com
-
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395812/#:~:text=SSRIs%20are%20generally%20better%20tolerated,agitation%20%5B8%2C89%5D.
About MindBio
Therapeutics
MindBio is a biotech/biopharma
company focused on creating novel and emerging treatments for
mental health conditions and is conducting world first take-home
LSD-Microdosing human clinical trials. MindBio is a leader in microdosing of
psychedelic medicines and is advancing its drug and technology
protocols through clinical trials. MindBio has developed a
multi-disciplinary platform for developing treatments and is
involved in psychedelic medicine development and digital
therapeutics, has completed Phase 1 clinical trials microdosing
Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2
clinical trial in development microdosing LSD in patients with
Major Depressive Disorder and a Phase 2 clinical trial in
development microdosing LSD in late stage cancer patients
experiencing existential distress. MindBio invests in research that
forms the basis for developing novel and clinically proven
treatments including digital technologies and interventions to
treat debilitating health conditions such as depression, anxiety
and other related mental health conditions.
Cautionary
Note Concerning Forward-Looking Statements:
The press release contains
"forward-looking statements" within the meaning of applicable
securities laws. Forward-looking statements can be identified by
words such as: "anticipate," "intend," "plan," "budget," "believe,"
"project," "estimate," "expect," "scheduled," "forecast,"
"strategy," "future," "likely," "may," "to be," "could," "would,"
"should," "will" and similar references to future periods or the
negative or comparable terminology, as well as terms usually used
in the future and conditional. Forward-looking statements are based
on assumptions as of the date they are provided. However, there can
be no assurance that such assumptions will reflect the actual
outcome of such items or factors.
Additionally, there are known
and unknown risk factors that could cause the Company's actual
results and financial conditions to differ materially from those
indicated in the forward-looking statements. Therefore, you should
not rely on any of these forward-looking statements. Important risk
factors that could cause actual results and financial conditions to
differ materially from those indicated in the forward-looking
statements, include among others: general economic, market and
business conditions in Canada and Australia; market volatility;
unforeseen delays in timelines for any of the transactions or
events described in this press release. All forward-looking information is
qualified in its entirety by this cautionary statement.
The Company disclaims any
obligation to revise or update any such forward-looking statement
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by
law.
Neither the Canadian Securities
Exchange nor its Regulation Service Provider (as that term is
defined in the policies of the Canadian Securities Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
